Financial Gravity Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Financial Gravity Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Hold	0	–	–	–	614
2019 Q4	$22K	Hold	2	–	–	0.02%	978
2019 Q3	$1K	Hold	2	–	–	﹤0.01%	1073
2019 Q2	$1K	Hold	2	–	–	﹤0.01%	1094
2019 Q1	$1K	Buy	+2	New	+$1.19K	﹤0.01%	1149
2018 Q3	$12K	Hold	22	–	–	0.01%	551
2018 Q2	$20K	Buy	22 +20	+1,000%	+$23.1K	0.02%	472
2018 Q1	$2K	Buy	+2	New	+$2.58K	﹤0.01%	978

Other funds holding NKTR

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Financial Gravity Asset Management's NKTR Position: Q4 2020 in Review

Financial Gravity Asset Management held its Nektar Therapeutics (NKTR) position steady in Q4 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Financial Gravity Asset Management first reported a position in NKTR in Q1 2018 and has held it in 7 quarters since. The position peaked at $22K in Q4 2019. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

Financial Gravity Asset Management held 0 shares of Nektar Therapeutics worth $0 as of Q4 2020.
Financial Gravity Asset Management left its Nektar Therapeutics share count unchanged in Q4 2020.
Nektar Therapeutics made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q4 2020, its #614 holding.
Financial Gravity Asset Management first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 7 quarters since.
Financial Gravity Asset Management's Nektar Therapeutics position peaked at $22K in Q4 2019.
246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Financial Gravity Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.